Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma

Loss of expression of human leukocyte antigen (HLA) class II molecules on tumor cells affects the onset and modulation of the immune response through lack of activation of CD4+ T lymphocytes. Previously, we showed that the frequent loss of expression of HLA class II in diffuse large B-cell lymphoma (DLBCL) of the testis and the central nervous system (CNS) is mainly due to homozygous deletions in the HLA region on chromosome band 6p21.3. A minority of cases showed hemizygous deletions or mitotic recombination, implying that mutation of the remaining copy of the class II genes might be involved. Here, we studied three DLBCLs with loss of HLA-DQ expression for mutations in the DQB1 and DQA1 genes and three tumors with loss of HLA-DR expression for mutations in the DRB1 and DRA genes. In one case, a point mutation in exon 2 of the DQB1 gene, leading to the formation of a stop codon, was detected at position 47. In a second case, a stop codon was found at position 11 due to a deletion of 19 bp in exon 1 of the DRA gene. No mutations were found in the promoter sequences of the DRA, DQA1 and DQB1 genes. We conclude that both homozygous deletions and hemizygous deletions or mitotic recombination with mutations of the remaining allele may lead to loss of expression of the HLA class II genes, which is comparable to the mechanisms affecting HLA class I expression in solid cancers.

[1]  O. Olerup,et al.  HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. , 1992, Tissue antigens.

[2]  Hishii,et al.  Studies of the mechanism of cytolysis by tumour‐infiltrating lymphocytes , 1999, Clinical and experimental immunology.

[3]  W. Vainchenker,et al.  Immunological study of in vitro maturation of human megakaryocytes , 1984, British journal of haematology.

[4]  C. Benoist,et al.  Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. , 1990, Annual review of immunology.

[5]  Santa Jeremy Ono,et al.  HLA-DRA promoter polymorphism and diversity generation within the immune system , 1997, Human Genetics.

[6]  E. Albert,et al.  A deletion in the second exon of an HLA-DRB1 allele found in a DR2-negative narcolepsy patient. , 1993, Human immunology.

[7]  J. Harton,et al.  Class II Transactivator: Mastering the Art of Major Histocompatibility Complex Expression , 2000, Molecular and Cellular Biology.

[8]  E. Jordanova,et al.  Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. , 2000, Blood.

[9]  G. Nepom,et al.  Ultrastructural allelic variation in HLA-DQB1 promoter elements. , 1995, Human immunology.

[10]  S. Westerheide,et al.  The MHC-Specific Enhanceosome and Its Role in MHC Class I and β2-Microglobulin Gene Transactivation1 , 2001, The Journal of Immunology.

[11]  S G Marsh,et al.  HLA class II region sequences, 1998. , 2008, Tissue antigens.

[12]  Julia G. Bodmer,et al.  IMGT/HLA Database--a sequence database for the human major histocompatibility complex. , 2001, Nucleic acids research.

[13]  E. Jordanova,et al.  Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B‐cell lymphomas of the testis and the central nervous system , 2002, Genes, chromosomes & cancer.

[14]  W R Mayr,et al.  Nomenclature for factors of the HLA system, 2002. , 2002, Tissue antigens.

[15]  G. Fleuren,et al.  Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer , 2000, The Journal of experimental medicine.

[16]  L. Glimcher,et al.  Sequences and factors: a guide to MHC class-II transcription. , 1992, Annual review of immunology.

[17]  O. Olerup,et al.  HLA‐DQB1 and ‐DQA1 typing by PCR amplification with sequence‐specific primers (PCR‐SSP) in 2 hours , 1993 .

[18]  J. Freed,et al.  Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Ottenhoff,et al.  Mycobacterium leprae-Specific, HLA Class II-Restricted Killing of Human Schwann Cells by CD4+ Th1 Cells: A Novel Immunopathogenic Mechanism of Nerve Damage in Leprosy1 , 2001, The Journal of Immunology.

[20]  P. A. Peterson,et al.  HLA-DR beta genes vary in number between different DR specificities, whereas the number of DQ beta genes is constant. , 1985, Journal of immunology.

[21]  R. Doebele,et al.  Novel glycosylation of HLA-DRalpha disrupts antigen presentation without altering endosomal localization. , 1998, Journal of immunology.

[22]  M. Kagnoff,et al.  Differential expression of HLA-DQA1 alleles associated with promoter polymorphism , 1997, Immunogenetics.

[23]  Steven G.E. Marsh,et al.  Nomenclature for factors of the HLA system , 1975 .

[24]  D. Vidovic,et al.  Selective apoptosis of neoplastic cells by the HLA-DR-specific monoclonal antibody. , 1998, Cancer letters.

[25]  F. Garrido,et al.  Rexpression of HLA class I antigens and restoration of antigen‐specific CTL response in melanoma cells following 5‐aza‐2′‐deoxycytidine treatment , 2001, International journal of cancer.

[26]  F. Bach,et al.  Detection of a novel human class II HLA antigen , 1983, Nature.

[27]  W. Reith,et al.  The bare lymphocyte syndrome and the regulation of MHC expression. , 2001, Annual review of immunology.

[28]  P. Stern,et al.  Multiple mechanisms underlie HLA dysregulation in cervical cancer. , 2000, Tissue antigens.

[29]  F. Garrido,et al.  MHC antigens and tumor escape from immune surveillance. , 2001, Advances in cancer research.

[30]  J. Trowsdale,et al.  Genetic Control of MHC Class II Expression , 2002, Cell.

[31]  M. Chamberlain,et al.  T-cell infiltration of primary CNS lymphoma , 1996, Neurology.

[32]  M. Kagnoff,et al.  Structure and evolution of the promoter regions of the DQA genes , 2004, Immunogenetics.

[33]  S. Stevanović,et al.  Epstein-Barr Nuclear Antigen 1-Specific CD4+ Th1 Cells Kill Burkitt’s Lymphoma Cells1 , 2002, The Journal of Immunology.

[34]  H. Petrie,et al.  CD4+ T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro , 2000, Cancer Immunology, Immunotherapy.

[35]  G. Yang,et al.  DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. , 2001, Carcinogenesis.

[36]  M. Tesar,et al.  Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells , 2002, Nature Medicine.

[37]  S. Kroft,et al.  Prognostic significance of tumour‐infiltrating T lymphocytes and T‐cell subsets in de novo diffuse large B‐cell lymphoma: a multiparameter flow cytometry study , 2001, British journal of haematology.

[38]  W. Reith,et al.  Promoter‐specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation , 2002, The EMBO journal.

[39]  Dominique Charron,et al.  Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency , 2002, Immunogenetics.

[40]  T. Habermann,et al.  Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.